Vassiliki Karantza
Overview
Explore the profile of Vassiliki Karantza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
12028
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dent R, Cortes J, Park Y, Munoz-Couselo E, Kim S, Sohn J, et al.
Breast Cancer Res
. 2025 Mar;
27(1):35.
PMID: 40069763
Background: The multicohort, open-label, phase 1b KEYNOTE-173 study was conducted to investigate pembrolizumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer (TNBC). This exploratory analysis evaluated features of the...
2.
Cardoso F, OShaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, et al.
Nat Med
. 2025 Jan;
31(2):442-448.
PMID: 39838117
Addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition of neoadjuvant pembrolizumab to chemotherapy would...
3.
Monberg M, Keefe S, Karantza V, Tryfonidis K, Toker S, Mejia J, et al.
Oncol Ther
. 2024 Oct;
12(4):701-734.
PMID: 39453600
Breast and gynecologic cancers are common across the world and are associated with substantial societal and economic burden. Pembrolizumab was among the first immune checkpoint inhibitors targeting programmed cell death...
4.
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kummel S, et al.
N Engl J Med
. 2024 Sep;
391(21):1981-1991.
PMID: 39282906
Background: In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing...
5.
Im S, Cortes J, Cescon D, Yusof M, Iwata H, Masuda N, et al.
NPJ Breast Cancer
. 2024 Sep;
10(1):79.
PMID: 39266535
In the phase 3 KEYNOTE-355 study (NCT02819518), pembrolizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) versus placebo plus chemotherapy among...
6.
Cortes J, Winer E, Lipatov O, Im S, Goncalves A, Munoz-Couselo E, et al.
J Pathol Clin Res
. 2024 Apr;
10(3):e12371.
PMID: 38627977
The efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD-L1) expression, as quantified by combined positive score (CPS; PD-L1 expression on both tumour cells and...
7.
Takahashi M, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, et al.
JAMA Netw Open
. 2023 Nov;
6(11):e2342107.
PMID: 37966841
Importance: In the phase 3 KEYNOTE-522 study, addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab significantly increased pathologic complete response (pCR) and event-free survival (EFS) vs neoadjuvant chemotherapy...
8.
Huang M, Fasching P, Haiderali A, Xue W, Pan W, Karantza V, et al.
Future Oncol
. 2023 Aug;
20(6):335-348.
PMID: 37602372
This study evaluated event-free survival (EFS) as a surrogate outcome for overall survival (OS) in neoadjuvant therapy for early-stage triple-negative breast cancer (eTNBC). Meta-regression analyses based on a targeted literature...
9.
Loi S, Salgado R, Schmid P, Cortes J, Cescon D, Winer E, et al.
JCO Precis Oncol
. 2023 Apr;
7:e2200317.
PMID: 37099733
Purpose: In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254)....
10.
Cortes J, Rugo H, Cescon D, Im S, Yusof M, Gallardo C, et al.
N Engl J Med
. 2022 Jul;
387(3):217-226.
PMID: 35857659
Background: In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast...